Psychedelic medicine (New Rochelle, N.Y.)
March 1, 2024
Jason Luoma, Luke R Allen, Veronika Gold et al.
14 citations
MDMA-assisted therapy (MDMA-AT) is nearing regulatory approval, but the role of therapeutic touch within it remains understudied and raises ethical concerns about power dynamics. A review of existing literature on touch in psychotherapy found little empirical evidence specifically for MDMA-AT. To address this gap, the authors developed the Touch Outcomes Measurement Inventory (TOMI), a tool for assessing clients' perceptions of touch during MDMA-AT. The creation of TOMI is the main outcome, intended to help researchers and evaluators study touch's impact and inform evidence-based, ethical guidelines for its use in MDMA-AT and other psychedelic-assisted therapies.
Jason B Luoma, Luke Roy Allen, Veronika Gold et al.
1 citation
preprint
MDMA is being tested as an adjunct to psychotherapy in controlled trials, including two completed Phase 3 trials, and could become a legally available medicine for MDMA-assisted therapy (MDMA-AT) within a few years. The treatment manual for MDMA-AT research considers touch an important part of therapy, but no empirical evaluation has examined how touch functions in MDMA-AT, and research on touch in psychotherapy generally is scarce. Concerns exist that touch combined with MDMA could intensify power imbalances or contribute to boundary crossings and unethical behavior.
June 4, 2026
Jason B Luoma, M. Kati Lear, Brian Pilecki et al.
preprint
MDMA-Assisted Therapy (MDMA-AT) produced a large reduction in social anxiety symptoms compared to a waitlist condition in adults with social anxiety disorder. In a randomized open-label trial of 20 participants, those receiving MDMA-AT showed an average decrease of 43.3 points on the Liebowitz Social Anxiety Scale after 16 weeks, while the waitlist group did not. Improvements also occurred in functioning, shame, acceptance, belongingness, self-concealment, and self-compassion. Adverse events were mild to moderate and temporary; no serious adverse events occurred. These preliminary findings suggest MDMA-AT is safe and feasible for social anxiety disorder and warrant further research.